542 Sonidegib tolerability across 30-months: Results from the phase 2 randomized BOLT trial

In the pivotal phase 2 BOLT study (NCT01327053), the hedgehog pathway inhibitor (HPI), sonidegib (Odomzo®), demonstrated significant clinical benefit and manageable tolerability in patients with locally advanced basal cell carcinoma (laBCC) in the primary analysis; here we present safety/tolerability from the 12-, 18- and 30-month follow-up analyses. Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE)...